Clinical Trial Update: Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy [Phase 4]

View source ↗

Summary

Phase 4 trial comparing vildagliptin and sitagliptin shows differences in their ability to lower fasting plasma glucose.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Galvus (vildagliptin)
• Januvia (sitagliptin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetes Mellitus Type 2 | Phase 4 | Status: COMPLETED